Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Gastroenterology
|
July 17, 2012
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus
Gary W Falk, Navtej S Buttar, Nathan R Foster, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
May 4, 2026
Randomized, Double-blind, Placebo-controlled Trial of Meriva® (curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Maria Gonzalez-Pons, Ricardo L Dominguez, Eleazar E Montalvan-Sanchez, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 6, 2019
Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms
Frank A Sinicrope, Pruthvi R Velamala, Louis M Wong Kee Song, et al.
Journal of the National Cancer Institute
|
August 12, 2020
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
John J McNeil, Peter Gibbs, Suzanne G Orchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Robert E Schoen, Lisa A Boardman, Marcia Cruz-Correa, et al.
Nature Medicine
|
January 16, 2026
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
Anna Morena D'Alise, Jason Willis, Fahriye Duzagac, et al.
Gut
|
July 10, 2020
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Reyes-Uribe, Wenhui Wu, Ozkan Gelincik, et al.
Frontiers in Immunology
|
June 4, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Ajay Bansal, Elena M Stoffel, Ramona Lim, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Gastroenterology
|
July 17, 2012
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus
Gary W Falk, Navtej S Buttar, Nathan R Foster, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
May 4, 2026
Randomized, Double-blind, Placebo-controlled Trial of Meriva® (curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Maria Gonzalez-Pons, Ricardo L Dominguez, Eleazar E Montalvan-Sanchez, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 6, 2019
Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms
Frank A Sinicrope, Pruthvi R Velamala, Louis M Wong Kee Song, et al.
Journal of the National Cancer Institute
|
August 12, 2020
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
John J McNeil, Peter Gibbs, Suzanne G Orchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Robert E Schoen, Lisa A Boardman, Marcia Cruz-Correa, et al.
Nature Medicine
|
January 16, 2026
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
Anna Morena D'Alise, Jason Willis, Fahriye Duzagac, et al.
Gut
|
July 10, 2020
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Reyes-Uribe, Wenhui Wu, Ozkan Gelincik, et al.
Frontiers in Immunology
|
June 4, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Ajay Bansal, Elena M Stoffel, Ramona Lim, et al.
Page
of 4